Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $143.43 Analyst target: $132.56 Upside: -7.58%
GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection (MCED). Utilizing proprietary genomic technologies, the company is committed to enhancing precision medicine by offering vital insights for proactive health management and improving patient outcomes. GRAIL is poised to address critical gaps in cancer screening and diagnostics, establishing itself as a pivotal entity in the dynamic oncology landscape, with the potential to significantly impact the future of cancer care.
See the full interactive analysis & chart →Informational only — not investment advice.